Multiple studies support flexible approach to treating actinic keratoses with imiquimod

In early March, the FDA granted marketing approval for use of imiquimod cream in the treatment of nonhyperkeratotic, nonhypertrophic AKs on the scalp or face in immunocompetent individuals.

Related Videos
Related Content

Q1 Accepted NDAs and sBLAs to Keep a Watchful Eye On

March 30th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Frontline Forum Part 4: A Discussion of the Pathophysiology of Acne and Available Treatment Strategies

March 30th 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

Dupilumab Safe and Effective in Moderate-to-Severe Atopic Dermatitis

March 30th 2023

Silybum Marianum Fruit Extract Safe, Effective in Acne-Prone Skin

March 29th 2023

Q1 Accepted NDAs and sBLAs to Keep a Watchful Eye On

March 30th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Frontline Forum Part 4: A Discussion of the Pathophysiology of Acne and Available Treatment Strategies

March 30th 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

Dupilumab Safe and Effective in Moderate-to-Severe Atopic Dermatitis

March 30th 2023

Silybum Marianum Fruit Extract Safe, Effective in Acne-Prone Skin

March 29th 2023

Q1 Accepted NDAs and sBLAs to Keep a Watchful Eye On

March 30th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Frontline Forum Part 4: A Discussion of the Pathophysiology of Acne and Available Treatment Strategies

March 30th 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

Dupilumab Safe and Effective in Moderate-to-Severe Atopic Dermatitis

March 30th 2023

Silybum Marianum Fruit Extract Safe, Effective in Acne-Prone Skin

March 29th 2023
© 2023 MJH Life Sciences

All rights reserved.